Treprostinil Sodium
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Treprostinil Sodium |
| DrugBank ID | DB00374 |
| Brand Names (EU) | Trepulmix |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.70% |
Approved Indication (EMA)
Treatment of adult patients with WHO Functional Class (FC) III or IV and: inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment to improve exercise capacity.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | pulmonary arteriovenous malformation (disease) | 99.70% | DL |
| 2 | pulmonary arterial hypertension | 99.62% | DL |
| 3 | pulmonary arterial hypertension associated with congenital heart disease | 99.60% | DL |
| 4 | pulmonary arterial hypertension associated with HIV infection | 99.55% | DL |
| 5 | pulmonary arterial hypertension associated with connective tissue disease | 99.55% | DL |
| 6 | pulmonary arterial hypertension associated with chronic hemolytic anemia | 99.55% | DL |
| 7 | pulmonary arterial hypertension associated with schistosomiasis | 99.55% | DL |
| 8 | hypotrichosis simplex of the scalp | 99.48% | DL |
| 9 | congenital hypotrichosis milia | 99.30% | DL |
| 10 | malformation syndrome with odontal and/or periodontal component | 99.21% | DL |
| 11 | Ambras type hypertrichosis universalis congenita | 99.17% | DL |
| 12 | diffuse alopecia areata | 99.17% | DL |
| 13 | hypertrichosis (disease) | 99.16% | DL |
| 14 | syndrome with a Dandy-Walker malformation as major feature | 99.12% | DL |
| 15 | isolated genetic hair shaft abnormality | 99.08% | DL |
| 16 | alopecia | 98.54% | DL |
| 17 | pulmonary hypertension, primary, autosomal recessive | 97.80% | DL |
| 18 | obsolete patella aplasia, coxa vara, and tarsal synostosis | 97.79% | DL |
| 19 | telangiectasia, hereditary hemorrhagic, | 97.50% | DL |
| 20 | familial clubfoot due to 17q23.1q23.2 microduplication | 97.33% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.